AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. Tuesday, the U.S. regulator greenlit GSK’s depemokimab, an ultra-long-acting ...

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications. CAMP4 ...

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay, in a new round of industry pacts with ...

GSK has surged ~46% YTD, far outpacing both the healthcare sector and S&P 500, which is notable considering the spectre of high US tariffs hanging over it. The recent US-UK pharmaceuticals deal, the ...

LONDON, Dec 16 (Reuters) - The U.S. health regulator has approved GSK's (GSK.L), opens new tab add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making manufacturing inroads in the U.S. by way of an acquisition. Samsung Bio’s U.S.

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...

Samsung Biologics said Monday it has inked a $280 million agreement to acquire GSK’s biopharmaceutical manufacturing plant in Rockville, Maryland, securing the Korean contract development and ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial ...